Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C5H10O5 |
Molecular Weight | 150.1299 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H](O)[C@H](O)[C@@H](O)C=O
InChI
InChIKey=PYMYPHUHKUWMLA-VAYJURFESA-N
InChI=1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h1,3-5,7-10H,2H2/t3-,4-,5+/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21548959Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/26652604 | https://www.ncbi.nlm.nih.gov/pubmed/21677059 | https://www.ncbi.nlm.nih.gov/pubmed/11863396
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21548959
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/26652604 | https://www.ncbi.nlm.nih.gov/pubmed/21677059 | https://www.ncbi.nlm.nih.gov/pubmed/11863396
L-Arabinose is a monosaccharide extracted from plant gums, corn fiber and beet pulps. It is a poorly-absorbed, readily-available sweet-tasting pentose. L-Arabinose is known to suppress obesity by regulating the fasting blood glucose level and the insulin resistance index. L-arabinose is a non-caloric sugar. L-arabinose may inhibit intestinal sucrase activity and thereby delay sucrose digestion.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2748 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21677059 |
2.8 mM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21548959
1,000 mg of l-arabinose and 200 ug of a patented food source chromium once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21677059
Caco-2 cells were cultured for 21 d, homogenized, and used as an enzyme preparation with sucrose as substrate in concentrations from 7 to 280 mmol/L with 0.84, 1.4, and 2.8 mmol L-arabinose/L as inhibitor. The addition of L-arabinose resulted in uncompetitive inhibition of sucrase activity on 25%, 29%, and 38%, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7261-25-8
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
ALTERNATIVE | |||
|
5460291
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | |||
|
100000127483
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | |||
|
782
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | |||
|
DTXSID9039733
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | |||
|
1941
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | |||
|
B40ROO395Z
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | |||
|
226-214-6
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | |||
|
201-767-6
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
ALTERNATIVE | |||
|
87-72-9
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
ALTERNATIVE | |||
|
5328-37-0
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | |||
|
m2020
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | Merck Index | ||
|
30849
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | |||
|
17535
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | |||
|
6182
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY | |||
|
SUB33509
Created by
admin on Fri Dec 15 19:31:32 GMT 2023 , Edited by admin on Fri Dec 15 19:31:32 GMT 2023
|
PRIMARY |
ACTIVE MOIETY